Breaking News

AbbVie Opens First Phase of Singapore Facility

New site to expand the company's global operations for small molecule and biologics manufacturing

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AbbVie has strengthened its manufacturing capabilities by opening the small molecule active pharmaceutical ingredient (API) facility of its Singapore manufacturing site. This facility supports the growth of AbbVie’s oncology and women’s health pipeline and reflects progress from AbbVie’s two previous announcements for manufacturing investment in Asia in 2014. The new 120,000 square-meter site located in the Tuas Biomedical Park is AbbVie’s first manufacturing facility ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters